J91.0

Malignant pleural effusion

Malignant pleural effusion (MPE) is a condition characterized by the accumulation of excess fluid in the pleural space that contains malignant cells. It is a common and serious complication of many advanced malignancies, signifying metastatic spread to the pleura or involvement of the pleural lymphatics. MPE occurs in approximately 15% of patients with cancer and is most frequently associated with lung cancer, breast cancer, and lymphomas. The fluid accumulation typically results from a combination of increased pleural capillary permeability due to cytokine release and impaired lymphatic drainage caused by tumor infiltration of the mediastinal lymph nodes. The presence of MPE generally indicates Stage IV (metastatic) disease and is associated with a shortened life expectancy and significant morbidity, primarily through respiratory compromise.

Clinical Symptoms

  • Progressive dyspnea (shortness of breath), initially on exertion and later at rest
  • Non-productive, dry cough
  • Pleuritic chest pain (sharp, localized pain during inspiration)
  • Dull, aching chest pain (more common in cases of mesothelioma)
  • Reduced exercise tolerance
  • Orthopnea (difficulty breathing while lying flat)
  • Unintentional weight loss and anorexia
  • Night sweats and persistent fatigue
  • Dullness to percussion over the affected lung area
  • Decreased or absent breath sounds on the side of the effusion
  • Diminished tactile fremitus

Common Causes

  • Metastatic lung cancer (most common cause, particularly adenocarcinoma)
  • Metastatic breast cancer
  • Lymphoma (both Hodgkin and non-Hodgkin)
  • Ovarian carcinoma
  • Primary pleural mesothelioma
  • Gastrointestinal malignancies (stomach, colon, and pancreatic cancers)
  • Renal cell carcinoma
  • Obstruction of mediastinal lymph nodes by tumor cells
  • Direct pleural invasion by adjacent thoracic tumors
  • Increased vascular permeability due to inflammatory cytokines released by tumor cells

Documentation & Coding Tips

Explicitly link the pleural effusion to the underlying malignancy to support the use of J91.0. Documentation should clarify if the effusion is a direct result of primary or secondary malignant process versus a non-malignant cause in a patient with cancer.

Example: Patient with Stage IV adenocarcinoma of the right lower lobe of the lung presents with increasing dyspnea. Chest X-ray reveals a large right-sided pleural effusion. Thoracentesis performed, and cytology confirmed malignant cells consistent with the known primary lung cancer. Diagnosis: Malignant pleural effusion (J91.0) secondary to malignant neoplasm of the right lower lobe, bronchus or lung (C34.31). The condition is currently being managed with therapeutic drainage and planned pleurodesis.

Billing Focus: Documentation must specify the primary or secondary malignancy first, followed by J91.0, to satisfy the Code first underlying neoplasm instructional note in ICD-10-CM.

Document the laterality of the effusion and the primary site of the cancer. While J91.0 is not itself laterality-specific, the accompanying primary malignancy codes and procedural codes often require laterality (e.g., right vs. left vs. bilateral).

Example: A 58-year-old female with metastatic breast cancer of the left upper-outer quadrant (C50.412) presents for evaluation of left-sided chest heaviness. Imaging confirms a new left malignant pleural effusion (J91.0). The patient is undergoing active palliative chemotherapy with Taxol.

Billing Focus: Specifying laterality in the clinical narrative supports the accuracy of procedural billing (e.g., CPT 32554 for right-sided thoracentesis).

Distinguish between malignant pleural effusion (J91.0) and pleural effusion in conditions classified elsewhere (J91.8) or non-malignant effusions. Clinical findings such as bloody fluid or positive cytology are key evidence.

Example: Diagnostic thoracentesis of the right pleural space yields 800cc of serosanguinous fluid. Cytopathology report indicates adenocarcinoma cells. The diagnosis of malignant pleural effusion (J91.0) is established as a manifestation of the patient's underlying mesothelioma of the right pleura (C45.0).

Billing Focus: Evidence-based documentation (cytology results) prevents audit denials for the high-weight J91.0 code.

Record the clinical status of the primary malignancy, such as whether it is active, metastatic, or in remission. J91.0 requires an active primary or secondary malignant diagnosis code to be sequenced first.

Example: The patient has a history of left-sided colon cancer, now with biopsy-proven secondary malignant neoplasm of the left lung (C78.02) and associated malignant pleural effusion (J91.0). Current management includes placement of a tunneled pleural catheter for recurrent symptomatic effusion.

Billing Focus: Using active malignancy codes instead of history of codes when an effusion is present is essential for compliant coding of J91.0.

Document the symptomatic manifestations caused by the effusion, such as pleuritic chest pain or dyspnea, to support the medical necessity of interventions like thoracentesis or pleurodesis.

Example: Patient reports severe dyspnea at rest (R06.02) and right-sided pleuritic chest pain (R07.81). Physical exam reveals absent breath sounds at the right base. Malignant pleural effusion (J91.0) is confirmed via ultrasound-guided drainage, which resulted in immediate symptomatic relief.

Billing Focus: Symptom documentation justifies the medical necessity of therapeutic procedures in accordance with Local Coverage Determinations (LCDs).

Relevant CPT Codes

Related Diagnoses

Hierarchy